GlassScriptPhysician profile
Nicholas A Cannarozzi
NPI 1194810259
$6,368.20
in general payments reported to CMS, 2019-2025
27 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,827 · 2020: $370 · 2021: $272 · 2022: $619 · 2023: $831 · 2024: $1,365 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,264 · Education: $17.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,263.67 |
| Education | $17.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,141.54 | 2019-2025 | Enbrel, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $992.74 | 2019-2025 | |
| Pfizer INC. | $984.09 | 2019-2025 | |
| Abbvie INC. | $732.52 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $394.09 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $331.64 | 2019-2025 | Orencia |
| Genentech USA, INC. | $320.79 | 2019-2020 | |
| Ucb, INC. | $271.68 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $269.65 | 2019-2024 | Taltz |
| Genzyme Corporation | $149.41 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $139.62 | 2019-2024 | Euflexxa |
| Aurinia Pharma U.S., INC. | $112.65 | 2024-2025 | Lupkynis |
| Sobi, INC | $101.28 | 2019-2023 | |
| Glaxosmithkline, LLC. | $80.24 | 2019-2020 | |
| Horizon Therapeutics Plc | $71.90 | 2020-2023 | Krystexxa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.30 | 2019-2024 | Cyltezo |
| Hikma Pharmaceuticals USA | $40.83 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $31.76 | 2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $29.70 | 2023-2025 | |
| Zimmer Biomet Holdings, INC. | $24.09 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Grifols USA, LLC | $19.54 | 2025 | Xembify |
| Celltrion USA INC. | $17.00 | 2023 | Yuflyma |
| Kiniksa Pharmaceuticals International, Plc | $15.75 | 2024 | Arcalyst |
| Sebela Pharmaceuticals INC. | $14.92 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.22 | 2019 | |
| Boston Scientific Corporation | $12.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Cannarozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.